DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07639021

Not yet recruitingPhase 2

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

25

Recruiting sites

—

Enrollment

230

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Number of gastrointestinal adverse events

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07639021
Org study IDNN9662-8649
Secondary IDU1111-1333-3475Universal Trial Number

Timeline

Milestones

Study start2026-06-09estimated
Study first posted2026-06-10actual
Last update posted2026-06-10actual
Primary completion2027-07-12estimated
Study completion2027-07-12estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Male or female (sex assigned at birth, inclusive of all gender identities).
•Age 18 years or above at the time of signing the informed consent.
•Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m^2) at screening.
•Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.

Exclusion criteria

•Known or suspected hypersensitivity to study intervention(s) or related products.
•Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.
•Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
•History of type 1 or type 2 diabetes mellitus.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
2
Safety / tolerability / PK
1

Weight & body composition

2 endpoints
Secondary/protocol endpoint

Relative change in body weight

Time frame:From week 0 to week 32

percent change from baseline, improvement

Secondary/protocol endpoint

Change in body mass index (BMI)

Time frame:From week 0 to week 32

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint

Number of gastrointestinal adverse events

Time frame:From week 0 to week 39

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.